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Abstract 
Alzheimer’s  disease  is  the fifth leading cause of death in the United States and the rate of diagnosis 
is increasing steadily. It is imperative to understand the pathology of the disease and its underlying 
mechanisms in order to develop potential therapies. This neurodegenerative disease involves 
neuronal death and brain atrophy associated with the presence of amyloid-β  plaques.  Alzheimer’s  
disease leads to impaired memory and cognitive skills, as well as the disruption of everyday tasks, 
such as movement and speech. Currently  there  is  no  cure  for  Alzheimer’s  disease; there are only 
therapies intended to manage symptoms. Our study focused on Caenorhabditis elegans models of 
Alzheimer’s  disease  and the ability of natural extracts to prevent the onset of symptoms caused by 
the disease. C. elegans is often used in the scientific community as a model organism due to the 
fact that its entire genome is sequenced and mapped, its neuronal connections are known – making 
research easier and more effective. We studied the effects of two polyphenols found in plants, 
punicalagin and tannic acid, as they have been shown to have antioxidant and anti-inflammatory 
properties, implicating neuroprotective effects. In this study, C. elegans behavioral assays were 
used to study the effects of punicalagin and tannic acid in combatting the effects of the amyloid-β  
peptide. These assays tested the chemosensation and the muscular deficits as  Alzheimer’s  disease  
can cause olfactory defects and paralysis in patients. Our results suggested that punicalagin reduces 
the neuronal deficits caused by the accumulation of the amyloid-β  peptide,  while  tannic  acid  was 
not shown to have a rescuing effect. 
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1 Introduction 
Alzheimer’s  disease  is  the  fifth leading cause of death in the United States, and is the only 
of the top ten deadly diseases that cannot be prevented, treated, or cured (Centers for Disease 
Control). This devastating disease has led to more deaths than both breast and prostate cancers 
combined. It is projected that the  number  of  new  Alzheimer’s  disease  diagnoses  will  triple  by  mid-
century (Gaugler, James and Johnson). Although the complete pathology of the disease is not fully 
understood, the most supported theory as to how the disease progresses is outlined in the Amyloid 
Cascade Hypothesis, depicted in Figure 4 on page 15 (Hardy and Selkoe). The hypothesis states 
that through the accumulation of an isoform of amyloid-β  protein  that  consists  of  42  amino  acids,  
extracellular plaques form, leading to neuronal death and neurodegeneration. This in turn causes 
the cognitive and physical symptoms exhibited by Alzheimer’s   patients   (Games, Adams and 
Alessandrini) 
Current therapeutic research on  an  Alzheimer’s  cure  and  symptom  alleviation is hindered 
by obstacles such as the selection of the right target of interest in the disease pathway, or the 
delivery of molecules across the blood brain barrier (Laterra, Keep and Betz).  Examples of 
possible targets include butyrylcholinesterase,  β- and  γ-secretases,  and  the  α7  nicotinic  receptor,  
all of which have been implicated as possible causative agents of the disease (Greig, Utsuki and 
Yu) (Kem) (Scarpini, Schelterns and Feldman). However, many of these targets also have other 
functions in the body, making it difficult to determine how they can be safely manipulated (Greig, 
Utsuki and Yu) (Kem) (Scarpini, Schelterns and Feldman). Therefore, study of potential therapies 
for challenging diseases  such  as  Alzheimer’s  disease  is  often  done  on  simpler  organisms,  which  
are commonly called model systems. These systems are organisms or cells that can be 
experimentally manipulated and used to understand biological functions. This data can be 
extrapolated to other organisms including humans, due to genetic conservation between species. 
 There are many organisms used as models  for  Alzheimer’s  disease  including  mice,  rhesus 
monkeys, and Caenorhabditis elegans (Van Dam and De Deyn). Commonly known as the 
roundworm, C. elegans is a nematode that has a nervous system which functions similarly to the 
human nervous system, but is simple enough to be studied in depth. Their body consists of 959 
cells, of which 302 are neurons and 81 are muscle cells. The network of connections between these 
neurons is completely mapped, allowing for a deeper understanding on the worm’s nervous 
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system, including genes, pathways, receptors, and molecules necessary for normal function. C. 
elegans can easily be genetically manipulated with very little cost. This allows for the insertion or 
deletion of genes of interest, which is very useful in the study of genetic diseases. Coupled with 
the  worms’  ease  of  propagation  and  high  rate  of reproduction, C. elegans is a great model organism 
to study neurodegenerative diseases  such  as  Alzheimer’s  disease (Kaletta and Hengartner). 
 We used C. elegans strains that were genetically modified to express the human amyloid-
β42 (Aβ42) transgene either pan-neuronally or pan-muscularly, in order to assess the behavioral 
effects of the peptide. Using three behavioral assays to evaluate either the chemosensory or 
muscular  phenotypes  of  the  worms,  we  characterized  the  behavioral  defects  caused  by  the  Aβ42 
transgene. We subsequently investigated the effects of treating the worms with plant-derived 
extracts, and the degree of alleviation of observed behavioral defects. 
A group of compounds that has been implicated as potential drug therapies for  Alzheimer’s  
disease is that of plant-derived extracts. Researchers have been focusing on natural extracts 
because historically these extracts have led to the discovery of effective drugs, such as morphine, 
and they are both cheap and readily available (Bastianetto and Quirion). Two compounds that have 
previously been found  to  have  rescuing  effects  against  the  symptoms  of  Alzheimer’s  disease  are  
punicalagin and tannic acid. Punicalagin and tannic acid are polyphenols with antioxidant and anti-
inflammatory properties, found in pomegranates and red wine, respectively (Olajide, Kumar and 
Velagapudi) (Ono, Hasegawa and Naiki). At the start of this study, there was no published data 
regarding these extracts being tested in C. elegans models  of  Alzheimer’s  disease.  Therefore, for 
our project, we investigated the effects of these natural compounds on C. elegans models of 
Alzheimer’s  disease. 
 Our results indicate that punicalagin prevented the onset of symptoms caused by Aβ42 that 
was expressed pan-neuronally, but not those caused by pan-muscular expression. In contrast, 
tannic acid did not have an effect on neither the chemosensory nor muscular defects that were 
caused by the peptide, and possibly even exacerbated the effects of Aβ42. It is possible that the 
concentration of tannic acid used in this project was too high, resulting in a toxic effect. From the 
conclusions gathered by this project, there are numerous directions that future research can take. 
Studies could investigate the neuroprotective mechanism of punicalagin, or assess the possibility 
of punicalagin as a retroactive treatment for Alzheimer’s  symptoms.  
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2 Background 
2.1 The Human Nervous System 
 The human nervous system transmits stimuli from sensory receptors throughout the body 
to the brain and spinal cord, before sending impulses back to the body in order to elicit a response 
(Matthews). The building blocks of the nervous system are small cells called neurons, which can 
be electrically excited. This allows neurons to transmit information through electrochemical 
signaling. This signaling is carried out by neurotransmitters: chemical messengers which relay, 
modify, and regulate information between neurons (Boeree). Neurons are incapable of dividing 
and cannot be regenerated: if a neuron dies, the functionality of that neuron is permanently lost. 
2.1.1 The Central and Peripheral Nervous System 
 The nervous system is functionally distinguished into two separate classifications: the 
central nervous system (CNS) and the peripheral nervous system (PNS) (Mangels). The CNS 
consists of the brain and spinal cord. The brain acts as the information processor and coordinates 
both conscious and unconscious body functions, while the spinal cord serves as the connection 
between the brain and the PNS (Timiras). The PNS consists of all other nerve cells throughout the 
body. Nerves of the PNS have either sensory or motor functions. Sensory neurons recognize 
changes in the environment by communicating with sensory receptors throughout the body, then 
relay information regarding these changes to the CNS. After processing, the CNS passes the 
information to the motor neurons that regulate muscle movement (Mangels). 
The motor neurons in the PNS can be further separated into two divisions: somatic 
(voluntary) and autonomic (involuntary). The somatic motor neurons are responsible for 
movement of skeletal muscles and function of sensory receptors under the skin (Swenson). The 
autonomic motor neurons regulate smooth muscles that cannot be controlled consciously, such as 
the heart and stomach (Mangels).  
2.1.2 The Function of a Neuron 
Neurons have four main structural components: the cell body, the dendrite, the axon, and 
the axon terminal. These structures can be seen in Figure 1. The cell body contains the nucleus, 
and is also a main location of protein synthesis. The rest of the neuron’s   structure   is   mainly  
involved with electrical signaling. First, a neuron receives chemical signals from other neurons at 
the dendrites. These signals are converted into electrical impulses and are then transmitted to 
axons. At the axon terminal, these impulses are converted back to chemical signals in the form of 
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neurotransmitters and released into the synapse, where they are received by the next neuron. The 
axon terminal is also involved in the reuptake of some of these neurotransmitters (Lodish, Berk 
and Zipursky). 
 
 
2.1.3 Neurodegeneration and Neurodegenerative Diseases 
Neurodegeneration is defined as the gradual loss of the structure or function of neurons, 
typically resulting in a deterioration of brain function (Przedborski, Vila and Jackson-Lewis). This 
may happen naturally due to aging, or as a result of various diseases. Several factors influence the 
potential for neurodegeneration including genetic mutations, toxic environmental factors, or a 
combination of the two (Przedborski, Vila and Jackson-Lewis). Currently, there is no drug for 
either treatment or prevention of these diseases. 
Some of the major neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), 
Huntington’s  disease,  Parkinson’s  disease,  and  Alzheimer’s  disease.  At  the cellular level, each of 
these diseases has been found to involve an abnormal buildup of proteins in the central nervous 
system, which leads to neurodegeneration and eventual neuronal death (Peden and Ironside). 
 ALS is a neurodegenerative disease that manifests as damage within the neurons located 
in   a   patient’s   spinal   cord.  This   damage  occurs   in   response   to   the   aggregation   of   ubiquitinated 
proteins (Blokhuis, Groen and Koppers). With the progressive degeneration of motor neurons in 
Figure 1. Neuron Structures. Electrical signals are received by dendrites, passed through the cell body and to the axons. At the 
end of the axons chemical signals are released to the next neuron through the axon terminals (Lodish, Berk and Zipursky). 
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this area, the brain loses its connection to the neurons that initiate and regulate muscle movement. 
The loss of muscle movement leaves patients unable to speak, eat, or breathe, which ultimately 
leads to death (ALS Association).  
 On  the  other  hand,  Huntington’s  disease  affects  the  brain  itself,  with  some  areas  being  more  
susceptible to damage than others. In this disease a protein called huntingtin is prone to misfolding 
and aggregation within the brain (Arrasate and Finkbeiner). One of the areas more susceptible to 
this aggregation is the basal ganglia, which is composed of nerve cell clusters called nuclei. These 
cells play an important role in both movement control and behavior, which explains why there is 
deterioration   of   these   actions   in   a   Huntington’s   disease   patient.   Huntington’s   disease   is   a  
genetically inherited, early onset disease, with symptoms appearing as early as 30 years of age 
(Huntington's Disease Society of America).  
 Parkinson’s  disease  typically  occurs  later  in  life,  and  is  characterized  by  clumps  of  proteins 
called Lewy Bodies, as well as neuronal death, primarily in an area of the brain called the 
substantia nigra. This neuronal death leads to decreased production of dopamine, which is involved 
in relaying information to the primary motor cortex and subsequently controlling voluntary motion 
and coordination.  The  decrease  in  dopamine  in  the  brain  causes  a  patient  with  Parkinson’s  disease  
to progressively lose the ability to control body movements. Except in rare cases of familial 
Parkinson’s  disease,  the  exact  cause  and  mechanism  of  the  protein  buildup  and  subsequent disease 
progression remains unclear (Parkinson's Disease Foundation). 
 Another  neurodegenerative  disease  that  typically  occurs  later  in  life  is  Alzheimer’s  disease.  
Alzheimer’s   disease   is   the   most   common   cause   of   dementia,   and   causes   memory   loss   and  
decreased cognitive ability. This disease is characterized by the accumulation of amyloid-β  and  
tau proteins within the brain that leads to eventual neuronal death. This disease inhibits an 
individual from performing everyday tasks, which eventually prevents him or her from living 
independently.   Ultimately,   Alzheimer’s   disease   leads to death (University of California, San 
Francisco). 
2.2 Alzheimer’s  disease 
 The  major  focus  of  this  research  project  was  Alzheimer’s  disease.  Attempts  were  made  to  
alleviate the symptoms displayed by C. elegans genetically engineered to express Aβ42. As such, 
a deeper understanding of the disease itself is necessary to put this research project into context. 
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The  following  section  will  further  discuss  the  current  state  of  Alzheimer’s  disease  understanding,  
prevalence, and drug development. 
2.2.1 Discovery, Prevalence, and Symptoms 
First described by Dr. Alois Alzheimer in 1906 (Alzheimer's Disease International), 
Alzheimer’s  disease  is  the  most  common  form  of  dementia.  It  currently  affects  approximately  5.3  
million Americans (Gaugler, James and Johnson), and is in the top five leading causes of death in 
the United States (Centers for Disease Control). The neuronal damage that occurs as a result of 
Alzheimer’s  disease  impairs  memory,  cognitive  skills,  and  performance  of  vital  bodily  functions, 
ultimately leading to death (Gaugler, James and Johnson). 
An   estimated   one   in   nine  Americans   aged   65   or   older   have  Alzheimer’s   disease. This 
frequency jumps to one in three for those aged 85 and older. However, this is likely an 
underestimate,  as  Alzheimer’s  disease  is  underdiagnosed.  Many  believe  that   the  disease  begins  
manifesting in an individual prior to the appearance of symptoms, an idea that, once validated, will 
likely increase the number of diagnoses (Gaugler, James and Johnson). 
Additionally, these statistics only take into account individuals who have died as a direct 
result  of  Alzheimer’s  disease, as described on their death certificate. This number underestimates 
the number of deaths resulting from the disease, as many acute conditions that lead to death, such 
as   pneumonia,   are   caused   by   the   complications   associated  with  Alzheimer’s   disease   (Gaugler, 
James and Johnson). These complications include immobility and malnutrition, both of which 
leave a patient more susceptible to other potentially deadly conditions. This blurred line between 
dying with the disease and dying from the disease implies that there are more deaths with 
Alzheimer’s   disease   as   the   underlying   cause   than   current   data   implies.   The   Alzheimer’s  
Association  explains  that  “[r]egardless  of  the  cause  of  death,  among  people  age  70,  61  percent  of  
those with Alzheimer’s  are  expected   to  die  before  age  80  compared  with  30  percent  of  people  
without  Alzheimer’s.” 
While the current diagnosis numbers are staggering, predictions for future incidence of 
Alzheimer’s  disease  diagnoses  are  significantly  worse.  As  of  2011,  the generation referred to as 
the  “baby  boomers”  began  to  reach  age  65.1 This generation has benefitted from modern medicine 
                                                          
1 The  term  “baby  boomers”  alludes  to  those born during the years 1946-1964. These were the years 
following World War II, when there was a sharp increase in the birth rate in the United States (L'Allier 
and Kolosh).  
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and public health advancements, leading to longer life expectancies than for their predecessors 
(L'Allier and Kolosh). These factors lead experts to project an almost threefold increase in the 
number  of  Americans  aged  65  or  older  with  Alzheimer’s  disease  by  2050   (Gaugler, James and 
Johnson). Figure 2 displays the predicted numbers  of  Americans  with  Alzheimer’s  disease  from  
2010 through 2050. Assuming these predictions are accurate, millions more Americans will die 
prematurely  as  a  result  of  Alzheimer’s  disease  in  the  coming  years.   
As  Alzheimer’s  disease  is  a  slow,  progressive  form  of  dementia,  the  majority  of  patients  
live many years with the disease. The average survival time for an individual diagnosed with 
Alzheimer’s  disease  is  4-8 years, but some patients live significantly longer (Gaugler, James and 
Johnson).  An  average  of  40%  of   the   time  living  with  Alzheimer’s  disease is spent in the most 
dependent stage of the disease (Gaugler, James and Johnson). In this final stage, patients are unable 
to carry out daily tasks or care for themselves, and typically either live with family or are admitted 
to a nursing home.  
When  family  members  of  Alzheimer’s  patients  take  on  caregiving  duties,   the  monetary,  
time, and emotional costs are enormous. It is estimated that these informal caregivers spent almost 
18 billion hours assisting individuals with Alzheimer’s  disease  in  2014  alone,  with  this  care  being 
valued at about $218 billion (Gaugler, James and Johnson). Out-of-pocket expenses related to 
Alzheimer’s   disease   for   patients   65   and   older   tend   to be more than $10,000 per year. These 
expenses double for patients living in nursing homes or assisted living. Additionally, individuals 
Figure 2. Projected Number of Americans Age 65+ with Alzheimer's Disease, 2010-2050 (Gaugler, James and 
Johnson). 
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with  Alzheimer’s  disease  accrue  “three  times  as  many  hospital  stays  per  year  as  other  older  people” 
(Gaugler, James and Johnson), leading to even more medical expenses. This monetary burden is 
not restricted to the individual families paying for treatment and care. Medicare and Medicaid are 
government programs that cover the majority of the expenses for low-income individuals. As a 
large  number  of  Alzheimer’s  disease  patients  rely  on  these  services  and  require  several  years  of  
treatment and care, the disease results in very high costs for these programs, translating to higher 
costs for taxpayers (Gaugler, James and Johnson). 
A  diagnosis  of  Alzheimer’s  disease  adds  emotional  stress  on  both  the  patient  and  his  or  her  
family.  There  are  many  difficulties  attributed   to  Alzheimer’s  disease,   such  as  dealing  with   the  
patient’s loss of judgment, understanding, and ability to communicate. Behavioral changes can 
also be difficult for a family member or friend to handle. Feelings of depression, guilt, and a lack 
of control are reported in the majority of caregivers (Gaugler, James and Johnson). Alzheimer’s  
disease affects the patient as well as their family and friends. 
2.2.2 Disease Pathology 
The  progressive   cognitive   decline   that   occurs   in  Alzheimer’s   disease   has   a   devastating  
effect on all aspects of the patient’s  life.  The  pathology  of  this  decline  is  not  yet  fully  understood,  
but  autopsies  of  Alzheimer’s  patients  have  led  to  the  conclusion  that  the  disease  causes  extensive  
neuronal death and brain atrophy. In fact, autopsy is currently the only way to definitively diagnose 
any individual  with  Alzheimer’s  disease (Perl).  
One component of this post-mortem   Alzheimer’s   diagnosis   is   the   presence   of  
neurofibrillary tangles (Perl). Neurofibrillary tangles are insoluble fibers found inside of neurons. 
They are mostly made up of tau proteins which are associated with microtubules (Paudel). 
Hyperphosphorylation of tau proteins within these neurofibrillary tangles is one of the hallmarks 
of  Alzheimer’s  disease,  and  the  amount  of  tangles  has  been  shown  to  correlate  with  both  the  length  
and degree of severity of the disease (Perl). 
15 
 
Amyloid   plaques   are   the   other   primary   component   of   Alzheimer’s   disease.   Similar   to  
neurofibrillary tangles, amyloid plaques are accumulations of insoluble protein fragments. These 
consist of amyloid-β  (Aβ)  peptides  that  stick  together  to  form  the  plaques (Games, Adams and 
Alessandrini). Unlike neurofibrillary tangles, these 
plaques are found outside of the neuronal body 
(Paudel). Both amyloid plaques and neurofibrillary 
tangles are shown in Figure 3. 
Though   the   exact   pathology   of   Alzheimer’s  
disease is not known, the most widely-accepted 
hypothesis is that the accumulation of amyloid-β  
peptide in the brain leads to disease development 
(Hardy and Selkoe). This hypothesis, known as the 
Amyloid Cascade Hypothesis, is summarized in Figure 4. Central to this hypothesis is Amyloid 
Precursor  Protein  (APP),  which  is  cut  by  γ-secretase and BACEs (β-APP 
cleaving enzymes) to form amyloid-β  (Karran, Mercken and De Strooper). 
The cut sites  of  γ-secretase vary, forming amyloid-β  fragments  that  range  
from 39-43 amino acids long. The most commonly found isoforms are 
either  40  or  42  amino  acids  long,  denoted  as  Aβ40 and  Aβ42, respectively 
(Karran, Mercken and De Strooper). The amyloid plaques found in 
Alzheimer’s  disease  are  made  up  of  primarily  Aβ42. Higher amounts of 
Aβ42 have been shown to correlate with higher levels of neuronal death 
(Gu, Guo and Zhefeng).  
While  Aβ42 leads to plaque formation, what causes the initiation of 
neurofibrillary tangle formation remains unknown. Current research 
suggests that the neurofibrillary tangles form after plaques, and may even 
be prompted by their formation (Hardy and Selkoe). This research has 
helped the Amyloid Cascade Hypothesis gain acceptance; however there are still some who argue 
Figure 4. Summary of the 
Amyloid Cascade Hypothesis 
Figure 3. Depiction of amyloid plaques and neurofibrillary 
tangles in an Alzheimer's disease patient (LaDu) 
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for a tau hypothesis, whereby tau aggregation is considered the causative agent for Alzheimer’s  
disease (Maccioni, Farías and Morales). 
 Regardless of whether the disease is prompted by amyloid plaque or neurofibrillary tangle 
formation,   the   high   rates   of   neuronal   death   in   Alzheimer’s   disease   lead   to   a   loss   of   synaptic  
connections within the brain. Without the ability to receive and transmit signals, the surviving 
neurons become non-functional as well. Eventually the degradation becomes widespread and the 
brain shrinks, as shown in Figure 5. The neuronal degradation and shrinking of the brain cause the 
cognitive symptoms and eventual death of Alzheimer’s   disease   patients   (National Institute on 
Aging). 
2.2.3 Current Treatments 
Although  Alzheimer’s  disease  has  been  studied  extensively  for  many  years,  there  are  many 
obstacles in the way of finding a cure. Uncertainty regarding the disease pathology has led to 
debate over what aspects of the disease should be targeted by therapeutics. A variety of clinical 
trials of therapies for prevention and treatment have been conducted, with limited success. Some 
of these therapies have included secretase inhibitors to prevent formation of amyloid-β   and  
promote amyloid-β clearance, anti-inflammatory drugs, cholesterol lowering drugs, and 
neuroprotective compounds to prevent disease onset and progression (Hardy and Selkoe). 
There are many obstacles to overcome when working with the brain. The blood brain 
barrier is the biggest obstacle in treating any disease of the brain. The blood brain barrier is the 
brain’s  specialized  “security  system”,  and  acts  to  allow  essential  nutrients  access  to  the  brain  while  
blocking potentially harmful chemicals. This barrier adds a layer of complexity to treating brain 
disorders, as it hinders drug delivery (Laterra, Keep and Betz). Potential therapeutics for 
Figure 5. Image showing a healthy brain (top left), an Alzheimer's disease brain (top right), and 
the two overlapped to directly show the size comparison (bottom) (Gaugler, James and 
Johnson). 
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Alzheimer’s   disease  must   be   engineered   so   that   they   are   able   to   pass   through   the   blood   brain  
barrier.  
Additionally,   many   of   the   molecules   involved   in   Alzheimer’s   disease’s   suspected  
pathology  are  also  involved  in  other  processes  in  the  body.  A  notable  example  of  this  is  γ-secretase. 
Because  γ-secretase  is  necessary  to  cut  APP  into  the  toxic  Aβ42, a potential therapeutic could be to 
inhibit   γ-secretase   in   order   to   eliminate   Aβ42 aggregation.   Unfortunately,   γ-secretase is also 
important to Notch protein and other cell surface receptor signaling (Hardy and Selkoe). Notch 
proteins are essential in cell signaling and development throughout the body (Kopan and Ilagan). 
As  such,  inhibition  of  γ-secretase would likely have many off-target consequences. 
2.3 Model Systems in Biology 
 Before  any  potential  treatment  for  Alzheimer’s  disease  can  be  tested  in  humans  it  must  be  
tested on model systems. In this research project the model system used was the nematode C. 
elegans, however there are a multitude of options for model systems when studying biology. 
 Model systems are used to study all aspects of biology – including simple biological 
functions, behaviors, diseases, and drug discovery. These systems can be as small as single cells 
or as large as whole populations. The criteria which govern whether or not an organism would 
make a good model system includes its size, life cycle, rate of reproduction, ease of maintenance, 
and ability to be manipulated for experimental purposes. By accruing large amounts of data 
regarding a few model organisms, scientists are able to extrapolate and predict how changing 
conditions may affect other organisms in terms of health and behavior (Kunkel). 
 Some model systems have long life cycles and are not ideal for genetic manipulation, but 
can be used to study behavior and reproduction. Examples of these model organisms include the 
chicken (Gallus gallus) and the frog (Xenopus laevis), which both breed multiple times each year. 
These models are large and complex, and have more in common with humans than smaller model 
organisms (Twyman). Some large, complex organisms, such as mice, are used to test the safety 
and efficacy of drug treatments prior to beginning clinical trials in humans (Steinmetz and Spack). 
 Organisms with short life spans that reproduce in large numbers allow for the study of 
genetics over generations. Genetic crosses can be performed and mutations can be introduced 
through various molecular methods. This allows for the study of specific gene functions and 
interactions (Twyman). Examples of genetic model organisms include the baker’s   yeast  
Saccharomyces cerevisiae, the fruit fly Drosophila melanogaster, and the nematode C. elegans. 
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2.3.1 C. elegans as a Model Organism 
 C. elegans is a model organism used to study various topics in biology. Of the phylum 
Nematoda, C. elegans are non-parasitic, free-living roundworms, 
which live in the soil, as well as in decaying fruits and vegetables 
throughout the world. These worms undergo morphogenesis 
including larval stages (denoted L1 through L4) and an adult stage, 
all of which are visible under a microscope. This developmental 
cycle lasts about two to three days when maintained 20°C, with 
different temperatures leading to different growth rates (Edgley). An 
adult worm is shown in Figure 6. 
 Various factors make C. elegans an ideal model organism for our research. C. elegans is 
easy to maintain in the lab – the worms can be grown on petri dishes containing Nematode Growth 
Medium (NGM) agar seeded with a bacterial food source, most commonly Escherichia coli. The 
ease and low cost of maintenance make C. elegans an effective tool for gathering large amounts 
of data. Another important factor is that the developmental cycle is both short as well as consistent 
between animals. This allows for experiments to be run quickly and at specific developmental 
stages (WormAtlas). Additionally, much is already known about C. elegans. In 1998 the entire 
genome of C. elegans was mapped, marking the first time an animal genome was sequenced (The 
C. elegans Sequencing Consortium). This provided a wealth of important genetic information that 
has aided in the understanding of gene function and provided the ability to perform genetic 
manipulations. These manipulations are easily maintained in a strain, as more than 99% of C. 
elegans are self-fertilizing hermaphrodites that produce up to 1,000 genetically identical progeny 
(Corsi). Years of research have led to the development of well characterized behavioral assays 
designed to test everything from simple behaviors such as foraging and sensory responses, to 
complex behaviors such as male mating, and learning and memory. 
2.3.2 C. elegans and  Alzheimer’s  disease 
 C. elegans is an effective model organism for the study of diseases. While it shares many 
characteristics with humans, including neuronal structure and communication, it is simple enough 
at the molecular and cellular level to be studied in depth (Hart and Chao). This allows for important 
insights into disease mechanisms and pathways that cannot be easily elucidated from more 
advanced organisms. As previously mentioned, about one third of the somatic cells in C. elegans 
Figure 6. Adult C. elegans under 
40X magnification 
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are neurons (Edgley). The neuronal network has been completely mapped, making C. elegans 
useful tools for studying diseases of the nervous system (Riddle).  
Aβ42 is  a  necessary  component  of  Alzheimer’s  disease pathology, and as such any model 
used to test the disease must include this protein. Unfortunately, C. elegans lack β-secretase, so 
Aβ42 cannot be produced from APP (Wolozin, Gabel and Ferree). In order to harness the power of 
the C. elegans model  organism  as  a  tool  to  study  Alzheimer’s  disease,  strains  were  created  by the 
Link lab at the University of Colorado to include the human Aβ42 transgene. This allowed for high 
throughput drug screening, similar to what is done with cultured neurons but with the added benefit 
of the organismal complexity of a living animal (Lublin and Link). The transgene was designed to 
express Aβ42 in either all of the neuronal or all of the muscle cells of the animal. The pan-neuronal 
transgene is expressed with a temperature sensitive promoter, so that Aβ42 is expressed when 
worms are exposed to temperatures above 20°C. Because of this, the worms must be propagated 
at 16°C. Two C. elegans strains expressing Aβ42 in muscle cells were engineered – one with the 
temperature sensitive promoter and one that constitutively expresses Aβ42. Originally only the 
constitutive model was created, but issues related to the age-dependent nature of the phenotype 
arose, leading to the creation of the temperature inducible strain (Lublin and Link).  
The existence of two types of Aβ42 expressing worms allows for a more complete 
understanding  of  Alzheimer’s  disease.  Those   expressing  Aβ42 pan-neuronally can be tested for 
changes in sensory abilities. One of the most important sensory abilities used by C. elegans to 
navigate in their environment is chemosensation. Chemosensation is used to detect the presence 
of food, predators, and potential mates. 
These environmental cues are detected by 
pairs of neurons located in the head of the 
worm called the amphid chemosensory 
neurons (Bargmann, Chemosensation in C. 
elegans). These neurons are displayed in 
Figure 7.   Tkalčić   et.   al discovered that 
human  Alzheimer’s   patients   have   deficits  
in odor identification abilities when compared to other elderly non-Alzheimer’s   patients,  
highlighting   the   translational   nature   of   research   into   Alzheimer’s   effect   on   chemosensation 
(Tkalčić,  Spasić  and  Ivanković).  
Figure 7. C. elegans amphid sensory neurons (Hart and Chao) 
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 Worms expressing Aβ42 in muscle cells, however, have been shown to have movement 
dysfunction, growth retardation, and shortened lifespans. These models allow for an investigation 
into the more physical symptoms of   Alzheimer’s   disease,   such   as   impaired   fine   motor skills 
(Wolozin, Gabel and Ferree). While memory loss is considered by many the hallmark symptom of 
Alzheimer’s  disease,  the  decreased  coordination  and  mobility  experienced  by  Alzheimer’s  patients  
is a significant complication that must also be addressed by researchers. 
2.4 Treatment Extracts 
 One advantage of using C. elegans as a model system for discovering potential therapeutics 
is the fact that the worms eat E. coli grown in liquid media. This allows researchers to administer 
compounds of interest via the E. coli media solution. This is called the LB Medium Method of 
drug delivery (Zheng, Ding and Li). In our study, C. elegans expressing Aβ42 were treated with 
various extracts through oral ingestion to determine whether an extract was able to mitigate 
behavioral symptoms caused by the Aβ42 expression. One criticism of this method is that the 
uptake of the drug is dependent on how much food the worms eat, unlike delivery studies with 
larger animals where exact doses can be administered either orally or intravenously. Zheng et al. 
analyzed C. elegans uptake of a drug using various methods of administration and found that the 
concentration of the drug following administration was comparable to levels observed in mice 
studies (Zheng, Ding and Li). 
Due  to  the  prevalence  of  Alzheimer’s  disease  as  well  as  other  cognitive  disorders  related  
to aging, many groups have begun to investigate the possibility of using natural extracts to prevent 
or reverse cognitive decline. Polyphenols are one class of extracts being examined, in part because 
they are cheap and readily available in modern diets (Bastianetto and Quirion).  Polyphenols can 
be found in a variety of plants, and are known to have both antioxidant and anti-inflammatory 
properties. As both oxidative stress and brain inflammation have been hypothesized as possible 
causes  of  Alzheimer’s  disease,  polyphenols  have  the  potential  to  be  used  as  therapeutics  (Manach, 
Scalbert and Morand). Preliminary research also suggests that most polyphenols are capable of 
crossing the blood brain barrier and localizing within brain tissue (Vauzour). If they are found to 
be effective, polyphenols could represent a powerful and cost effective therapeutic tool for the 
prevention  or  treatment  of  Alzheimer’s  disease.  The  two  polyphenols   investigated  in   this  study  
were punicalagin and tannic acid. 
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2.4.1 Punicalagin 
Punicalagin is a polyphenol commonly found in pomegranates. The name punicalagin is 
derived from the words Punica granatum, the scientific name for pomegranate. While punicalagin 
can be found in other plants, the highest concentration is found in pomegranates. Pomegranate is 
known to have several health benefits because of its high concentration of antioxidants, as well as 
its antibacterial and antifungal properties. These properties can aid in cardiovascular protection 
and anti-aging. As an antioxidant, punicalagin neutralizes free radicals, therefore having a positive 
effect on aging by reducing aging symptoms, such as dementia. The theory of the role of free 
radicals in aging is that unstable oxygen atoms, having one unpaired electron in their outer shell, 
are in search of a complementary partner and thus are extremely chemically reactive, which 
destroys cells. Punicalagin attaches and binds to these free radicals, inhibiting them from damaging 
other cells. Other benefits of punicalagin include prevention of low density lipoprotein (LDL) 
cholesterol oxidation, protection against UV radiation, and reduction of blood pressure (Gailee 
Nutritionals). 
At the University of Huddersfield in Germany, Dr. Olajide and his coworkers have 
established that punicalagin can help reduce neuro-inflammation in non-neuronal brain cells called 
microglia. This inflammation is one proposed cause of dementia and Alzheimer’s  disease.  Rat  
primary microglia cells were isolated and tested with the extract at 5-40 µM for 30 minutes. 
Researchers found that punicalagin inhibited TRAF-6 mediated neuroinflammation, providing 
evidence to its possibility as a possible therapeutic for neuroinflammatory diseases such as 
Alzheimer’s  disease  and  Parkinson’s  disease  (Olajide, Kumar and Velagapudi). 
2.4.2 Tannic Acid 
Tannic acid is another polyphenol, formed from a class of molecules called gallotannins. 
This polyphenol shares many properties of punicalagin, most importantly the antioxidant activity. 
It is already widely used in medicine, specifically for treating burns, poisoning, and diarrhea. 
Tannic acid is commonly found in red wine, meat products, and many plants, but is toxic at very 
high levels in the blood stream (Khan, Ahmad and Hadi). 
Many studies have already been conducted in regards to using tannic acid to treat cancer, 
and it has been shown to reduce the risk of tumor formation (Khan, Ahmad and Hadi). Research 
has also shown that some wine-derived polyphenols can inhibit the formation of Aβ42 in vitro. 
More specifically, tannic acid was shown to both inhibit Aβ42 formation and destabilize Aβ42 that 
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was already formed. The effective concentration (EC50), or concentration that induced a response 
halfway between the baseline and maximum effect, was found to be below 0.1 µM (Ono, 
Hasegawa and Naiki). These in vitro tests were promising, and such low concentrations could 
easily be administered to patients without nearing toxic levels. Although the mechanism of action 
remains unclear, tannic acid is a suitable compound to study for the treatment and prevention of 
Alzheimer’s  disease. 
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3 Methodology 
The following chapter outlines the methodology used in this project including the strains 
of C. elegans that were tested and the assays used to characterize effects on behavior.  
3.1 Worm Strains 
All strains used in this study were obtained from the Caenorhabditis Genetics Center 
(CGC). The wild-type strain, isolated in Bristol, UK, termed N2, was used to record the baseline 
data for all assays. The two strains of  Alzheimer’s  disease  C. elegans used in this study exhibited 
pan-neuronal or pan-muscular expression of a human Aβ42 transgene. The pan-neuronal strains 
were tested using chemotaxis and avoidance assays, while the pan-muscular strains were used in 
a thrashing assay. Strain CL2355 (smg-1ts; dvIs50 [pCL45 (snb-1::Aβ  1-42::3' UTR(long) + mtl-
2::GFP]) is a heat inducible neuronal mutant due to the temperature-sensitive smg-1ts background. 
It expresses Aβ42 under the synaptobrevin (snb-1) promoter in all neurons when exposed to a heat 
shock of at least 23°C. The control for this chemosensory mutant is strain CL2122 (smg-1ts; dvIs15 
[(pPD30.38) unc-54(vector) + (pCL26) mtl-2::GFP]), which contains the same inserts and 
transgenes as CL2355 excluding the human Aβ42 transgene. The pan-muscular strains were 
CL4176, CL2006, and CL802. CL4176 (smg-1ts; dvIs27 [(pAF29)pmyo-3::Aβ (1-42)::let-? 
3'UTR) + (pRF4)rol-6(su1006)]) is a heat inducible strain due to smg-1ts background that expresses 
Aβ42 at 23°C, causing muscular deficiency. CL2006 (dvIs2 [pCL12(unc-54/human Aβ peptide 1-
42 minigene) + pRF4]) constitutively expresses Aβ42 without the need for a heat induction. CL802 
(smg-1(cc546); rol-6(su1006)) is the control strain for CL4176, because it possesses the same smg-
1 background, without the Aβ42. Furthermore, CL802 is also a control strain for CL2006 because 
it possesses the rol-6 gene, which gives rise to the roller phenotype. This phenotype causes the 
worms to be helically twisted and roll when they move (CGC). 
3.2 Worm Maintenance 
C. elegans were grown on standard Nematode Growth Medium (NGM) plates seeded with 
the OP50 strain of E. coli grown in LB Media as the food source (Stiernagle, 2006). Worms were 
grown on plates with or without rescue extracts, and maintained at either 20°C (N2 strain) or 16°C 
(N2, CL2122, CL2355, CL4176, CL2006, and CL802 strains). Although 20°C is the most 
commonly accepted temperature for C. elegans growth, the temperature sensitive background of 
the  strains  expressing  Alzheimer’s  phenotypes  necessitated  growth  at  16°C.  
24 
 
Worms were transferred to new plates when food became scarce in order to prevent 
starvation. Transfer was accomplished with a homemade worm pick made with a flattened 
platinum wire mounted in the tip of a glass Pasteur pipette. The end of the wire was flame sterilized 
and then gently lowered to pick up one or more worms. The wire was then brought to the surface 
of a fresh, seeded NGM plate and held in place until the worm crawled onto the agar. All worm 
maintenance practices done are commonly used in the worm community as detailed by WormBook 
(Stiernagle, 2006).  
3.3 Addition of Rescue Extracts to LB Media and OP50 
In order to treat C. elegans with various extracts, each extract had to be diluted to an 
appropriate concentration. The extracts were delivered to the worms by mixing them with their 
food in LB media. The concentrations used for each extract were determined by searching primary 
literature. 
3.3.1 Punicalagin 
Based on the work by Oladije et al., 2.7 mg of 40% punicalagin was diluted in 0.27% 
ethanol and then added to 100 mL of ultrapure water. This solution was then filtered sterilized 
using a 0.20 µm SteritopTM filter unit. In order to achieve a final concentration of 2.7 mg/200 mL 
or 1.2 x 10-5 M, 100 mL of LB media previously inoculated with OP50 E. coli was added to the 
sterile punicalagin solution.  
3.3.2 Ethanol Control 
As a control for the punicalagin solution, a control LB media with 0.27% ethanol was 
made. 270 µL of 100% ethanol was added to 100 mL of media and OP50 solution. 
3.3.3 Tannic Acid 
Based on the work by Ono et al., 3.4 mg of tannic acid was measured and diluted in 100 mL 
of ultrapure water. 10 mL of this solution was added to 90 mL of ultrapure water. Finally, 10 mL 
of this dilution was then added to 90 mL of LB media, resulting in a final concentration of 0.034% 
tannic acid. In contrast to the methods used to make the punicalagin solution, the LB media added 
had not been previously inoculated with OP50 E. coli. The tannic acid and LB media solution was 
then filter sterilized using a 0.20 µm SteritopTM filter unit. This sterile tannic acid and LB media 
solution was then inoculated with OP50 E. coli and incubated overnight at 37°C to achieve a final 
concentration of 2 x 10-5 M. 
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3.4 Heat Shock Procedure 
Worms were initially grown at 16°C. 20-30 L1 staged animals were passed onto a new 
seeded plate. There are two methods used to induce the Aβ42 expression by temperature upshift.  
The first method utilized a water bath to upshift the temperature. Two strips of parafilm were 
wrapped tightly around the edge of the plate to seal the gap between the plate and the lid. The 
plates were inverted and placed in a 23°C water bath. The plates were collected under a tube rack, 
and a 1 kg weight was placed on top of the rack. This kept the plates fully submerged and at a 
constant water pressure throughout the duration of the temperature upshift. Plates were left in the 
water bath for 36-48 hours. After at least 36 hours had passed, plates were taken out of the water 
bath and the parafilm was removed. Plates were wiped dry and left inverted on the bench top at 
room temperature for one hour. After one hour, worms were tested with the avoidance assay. 
The second method used to induce the Aβ42 expression was by use of a 25°C incubator. 
Following passage of L1 staged worms to a new seeded plate, plates were inverted and placed in 
a 25°C incubator for 36-48 hours. After at least 36 hours, plates were taken out of the incubator 
and were let to acclimate to room temperature for one hour, after which, the worms were tested on 
either the chemotaxis or thrashing assays. The water bath heat shock method was tested for the 
chemotaxis methods, however baseline results were lower than normal and the plates had a 
tendency to become contaminated, so the incubator was used instead. These problems were not 
seen with the avoidance assay, so the water bath continued to be used. 
3.5 Avoidance Assay 
10 adult worms were picked from a seeded plate onto an unseeded NGM plate. After one 
minute of acclimation time, the worms were tested with the drop assay as originally described by 
Hilliard in 2004 (Hilliard, Bergamasco and Arbucci). 
In this assay, 10  μl glass capillaries were pulled over a flame to create a thin micro needle 
tip. The capillary was then inserted into a micro-pipetting apparatus. A 5 nanoliter drop was 
delivered by mouth to the tail of a forward moving worm. Capillary action caused the drop to 
surround the worm, traveling forward from the tail to the head of the worm, eventually reaching 
the chemosensory neurons located at the anterior tip of the animal. A response of a full reversal, 
omega turn, or turn greater than 90° within four seconds of drop administration was scored as an 
avoidance response. If the worm continued forward motion after drop administration, this was 
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scored as   “no   avoidance”   (Hart and Chao). A depiction of the responses of no avoidance and 
avoidance is displayed in Figure 8. 
 
M9 buffer containing 0.1% sodium dodecyl sulfate (SDS) was used as the repellant, with 
M9 buffer used as a vehicle control. SDS is a synthetic organic chemical often used in cleaning 
products whereas M9 buffer is a salt solution often used to wash and prepare worms for freezing 
(JoVE Science Education Database). To make 0.1% SDS, 5 μl  of 20% SDS was added to 995 μl 
of M9 buffer. M9 buffer is made up of 3.0g KH2PO4, 6.0g Na2HPO4, 0.5g NaCl, and 1.0g NH4Cl 
mixed with enough water to bring the mixture to 1L (Riddle, Blumenthal and Meyer).  
One drop of the SDS was placed on each worm, and the response was recorded. A timer 
was set and the worms were left alone for two minutes. After two minutes, one drop of SDS was 
again placed on each worm and responses were recorded. This was done three times with each 
solution, resulting in six drops of solution being placed on each worm tested. 
In order to determine the ratio of worms that avoided the avoidance chemical to those that 
did not avoid, an avoidance index was calculated. The index is normalized to exclude worms that 
also avoided the control chemical. As depicted in Figure 9, this is accomplished by calculating the 
number of worms that avoided the control subtracted from the number of worms that avoided the 
SDS. This was then divided by the total number of worms tested to produce an avoidance index 
between 0 and 1. A higher avoidance index indicated a higher level of avoidance to that chemical. 
 
𝐴𝑣𝑜𝑖𝑑𝑎𝑛𝑐𝑒  𝐼𝑛𝑑𝑒𝑥 =
𝑊𝑜𝑟𝑚𝑠  𝐴𝑣𝑜𝑖𝑑𝑖𝑛𝑔  𝑆𝐷𝑆 −𝑊𝑜𝑟𝑚𝑠  𝐴𝑣𝑜𝑖𝑑𝑖𝑛𝑔  𝑀9
𝑇𝑜𝑡𝑎𝑙  𝑊𝑜𝑟𝑚𝑠  𝑇𝑒𝑠𝑡𝑒𝑑  
Figure 9. Equation to calculate avoidance index. 
 
Figure 8. Example of avoidance and no avoidance in the drop assay. The red arrow points towards the 
direction of forward motion. (Adapted from Chute). 
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3.6 Chemotaxis Assay 
At the beginning of this study, an attraction assay was used to determine the length of time 
that the worms spent directly within an attractant solution as compared to the time spent in a 
vehicle control of ultrapure water. The initial intention was to assess the effect of the neuronal 
expression by CL2355 through extrapolating attraction data as an indication of chemotaxis ability. 
Unfortunately, this extrapolation could not provide the necessary data because it did not highlight 
each worm’s chemosensory abilities, so a different assay had to be utilized (See Appendix 6-3 for 
procedure of attraction assay). An assay designed to directly measure chemotaxis in C. elegans 
was selected and used for the remainder of the study (Ward).  
The final chemotaxis assay used was based on an assay developed by Samuel Ward in 
1973. After testing both diacetyl and isoamyl alcohol (IAA) to determine which chemical had a 
more robust response in the chemotaxis assay, it was decided that IAA (10-2 dilution) would be 
the chemical used going forward. The protocols for 
dilutions of both chemicals can be found in Appendix A 
and B. 
Assay plates were made from 2% agar, 5 mM 
KPO4 pH 6.0, 1 mM CaCl2, and 1 mM MgSO4, poured into 
a 10 cm petri dish. Two small marks were made 180 
degrees apart on the bottom of the plate. In Figure 10, these 
marks are noted as A and C. 1 μL  of  1  M  sodium  azide  
(NaN3) was placed on each mark in order to paralyze 
worms once they were in close proximity to the marks.  
 To prepare for the assay, approximately 100 worms 
were removed from a seeded plate and washed three times using S. Basal, a mild solution used to 
remove traces of food or eggs from the worms, in a 1.5 mL microcentrifuge tube. S. basal is a salt 
buffer made of 5.85g NaCl, 1g K2HPO4, 6g KH2PO4, 1mL cholesterol in ethanol, and enough 
water to fill to 1L (Stiernagle). Following the three washes, the worms were washed once with 
ultrapure water to remove any residual S. Basal. 10 μL of the washed worms were then transferred 
to the origin point (located in the center of the plate) as seen in Figure 10. Excess liquid was then 
carefully removed using a KimWipe. 1 μL of IAA and ultrapure water was placed on the A and C 
marks, respectively. The lid of the plate was immediately closed following the placement of the 
Figure 10. Design of chemotaxis assay. Worms 
are placed on the origin spot (Bargmann, 1993). 
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chemicals to contain the odor of the chemicals, as IAA is volatile. The assay was run for one hour, 
during which, the plates were continually checked for clumping of the worms at the origin point. 
If clumping was observed the worms were gently dispersed with a pick. At the end of the hour, the 
number of paralyzed worms in each chemical was counted. A chemotaxis index was then 
calculated using the following equation: 
 
𝐶ℎ𝑒𝑚𝑜𝑡𝑎𝑥𝑖𝑠  𝐼𝑛𝑑𝑒𝑥 =   
𝑊𝑜𝑟𝑚𝑠  𝑎𝑡  𝐴𝑡𝑡𝑟𝑎𝑐𝑡𝑎𝑛𝑡 −𝑊𝑜𝑟𝑚𝑠  𝑎𝑡  𝐶𝑜𝑛𝑡𝑟𝑜𝑙
𝑇𝑜𝑡𝑎𝑙  𝑊𝑜𝑟𝑚𝑠  𝑇𝑒𝑠𝑡𝑒𝑑  
Figure 11. Equation to calculate the chemotaxis index of one test plate. 
 
3.7 Thrashing Assay 
A thrashing assay developed by Brenner et al. in 1974 was 
optimized to test impaired movement caused by the expression of 
pan-muscular Aβ42. An adult worm was picked from a seeded NGM 
plate and placed on an unseeded NGM plate, where it was allowed 
to crawl around for one minute in order to remove any residual OP50 
E. coli. It was important for the bacteria to be eliminated, as it could 
alter  the  worm’s  movement  during  the  assay. 
After a few assay design iterations, the lid of a 48-well plate 
was chosen for the setup, with the circular outlines of the lid filled 
with 100 µl of M9 buffer, as seen in Figure 12. 
When the isolated worm was clear of E. coli, it was picked from the 
unseeded plate and placed in the 
middle of an M9 drop. The worm was left in the drop for one 
minute to allow it to acclimate to the environment. The thrashes of 
the worm were then recorded for one minute using the WormLab 
Image Acquisition software by MBF Biosciences. Following one 
minute of thrashing, the video was analyzed using the WormLab 
Analysis  software.  The  worm’s  mid-point bending angle, shown in 
green in Figure 13, was analyzed by the software. A total of four 
worms were tested for each strain and condition. 
Figure 12. Lid of a 48-well plate 
used for thrashing assay with 100 
µl of M9 buffer. 
Figure 13. Display of mid-point bending 
angle of C. elegans (WormLab). 
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4 Results and Discussion 
Based on the previously described methodology, the following chapter outlines the results 
obtained from the avoidance, chemotaxis, and thrashing assays of worms grown on OP50, OP50 
and Punicalagin, OP50 and ethanol, and OP50 and Tannic Acid, as well as comparisons between 
treatment conditions. 
4.1 Baseline Testing 
In order to determine baseline data the three assays were run with wild type (N2), control 
(CL2122, CL802), and transgenic strains (CL2355, CL4176). These strains were grown on NGM 
plates seeded with LB media + OP50 E. coli. Testing was performed on unseeded plates. 
4.1.1 Avoidance Assay 
Testing the chemosensory ability 
of N2 worms using the avoidance assay 
yielded an average avoidance index of 
0.76 ± 0.02973, when propagated at 
20°C, consistent with the results from 
Hillard et al. in 2002 (Hilliard, 
Bergamasco and Arbucci). Figure 14 
shows the avoidance indices for all 
worms grown on normal OP50. The 
avoidance index of N2 worms grown at 
temperatures other than 20°C was 
slightly lower, however this lower 
avoidance index was consistent between 
N2 and CL2122. CL2355 at 16°C was 
consistent with the N2 at 20°C. 
Evidence of chemosensory deficit caused 
by  the  expression  of  Aβ42 peptide is demonstrated by the significantly lower avoidance index of     
CL 2355 worms at 23°C (0.33 ± 0.04877), compared to CL 2122 at 23 °C (0.64 ± 0.03239, as well 
as compared to CL2355 without a temperature upshift, 0.76 ± 0.02860 (p < 0.0001, one-way 
ANOVA,  Bonferroni’s  correction).  This  indicates  that  Aβ42 expression caused the worms to lose 
their ability to sense and respond to the aversive cue, indicating a chemosensory deficit. 
Figure 14. Avoidance index of N2, CL2122, and 
CL2355 at various temperatures on NGM plates. 
Avoidance Index of C.elegans Grown on 
OP50 with 0.1% SDS in M9 
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4.1.2 Chemotaxis Assay 
N2 worms propagated at 
20°C are expected to have a 
chemotaxis index of about 0.80 
(Bargmann, Hartwieg and 
Horvitz, Odorant-selective genes 
and neurons mediate olfaction in 
C. elegans). In this study, a 
chemotaxis of 0.78 ± 0.03952 was 
obtained for N2 worms grown at 
20°C, consistent with these 
results. Figure 15 shows the 
chemotaxis indices for all worms 
grown on normal OP50. 
The chemotaxis index of N2 
worms grown at 20°C, 16°C (0.78 
± 0.02048) and 25°C (0.81 ± 
0.04081) was not significantly different. CL2122 worms had a similar chemotaxis index at each 
temperature (0.78 ± 0.02835 at 16°C and 0.75 ± 0.04133 at 25°C), while CL2355 was slightly 
lower with the upshift of temperature  (0.25  ±  0.1162).  The  expression  of  Aβ42 peptide following 
temperature upshift led to a reduced chemotaxis index compared to CL2355 without the upshift 
(0.61 ± 0.06706) (p = 0.0003, one-way  ANOVA,  Bonferroni’s  correction).  There  is  a  significant  
difference of the chemotaxis index between CL 2122 at 25 °C and CL 2355 at 25°C (p < 0.0001, 
one-way  ANOVA,  Bonferroni’s   correction). This again indicated a reduction in chemosensory 
abilities in response to Aβ42 expression. 
4.1.3 Thrashing Assay 
A thrashing assay was  performed  to  evaluate  the  effect  of  Aβ  expression  on  muscle  cells.  
Figure 16 shows the average thrash count per minute for N2, CL802, and CL4176 grown on OP50. 
The average thrash count per minute of an N2 worm grown at 20°C was 139.50 ± 19.53 thrashes. 
CL 802 had a significantly reduced thrash count per minute at 52.50 ± 6.035 thrashes. This can be 
Figure 15. Chemotaxis Index of N2, CL 2122, and CL 2355 at 
various temperatures on regular NGM plates. 
Chemotaxis Index of C.elegans Grown 
on OP50 with 10-2 IAA 
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explained by the roller phenotype that 
both CL 802 and CL 4176 have.  This 
phenotype causes the worms to roll in 
order to move, instead of crawl.  
 The  effect  of  the  Aβ42 peptide 
can be seen when CL 4176 was 
propagated at 25°C. There is a 
significant difference in the number of 
thrashes with and without the upshift 
in temperature (53.25 ± 11.46 at 16°C 
and 20.50 ± 7.005 at 25°C)                       
(p = 0.0417, one-way ANOVA, 
Bonferroni’s   correction).   This  
indicates that   the   expression   of   Aβ42 
caused impaired movement. There was 
no significant difference between      
CL 802 grown at different temperatures, nor between CL802 and CL4176 following temperature 
upshift. 
4.2 Punicalagin 
To assess the effects of punicalagin on the phenotypes   seen   in   strains   expressing  Aβ42 
peptide,  all  strains  were  grown  on  NGM  plates  seeded  with  OP50  and  12  μM  punicalagin  with  
0.27% ethanol. The ethanol was added to dissolve the punicalagin in the OP50. To control for the 
added ethanol, all strains were grown on OP50 with 0.27% ethanol and tested with each assay. 
4.2.1 Avoidance Assay 
The same avoidance assay was used to test the chemosensation ability of worms treated 
with punicalagin. N2 worms grown on OP50 with punicalagin at 20°C had an avoidance index of 
0.49 ± 0.1076. This result was lower than expected because of one trial with an abnormally high 
control response. However, the rest of the data was consistent with normal values of about 0.80. 
Figure 17 shows the avoidance indices for all worms grown on OP50 with punicalagin. 
Figure 16. Thrash count per minute of N2, CL802, and CL4176 at various 
temperatures on regular NGM plates. 
Thrash Count per Minute of C. elegans 
Grown on OP50 in M9 
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 The lower avoidance index caused by 
the pan-neuronal   expression   of   Aβ42 was 
alleviated when worms were grown on 
OP50 with punicalagin, as evidenced by 
the fact that the avoidance index of             
CL 2355 at 23°C, 0.74 ± 0.01235, was not 
significantly different from that of CL 2355 
at 16°C, 0.70 ± 0.03651 or of CL 2122 at 
23°C, 0.61 ± 0.05004 (p > 0.9999 and p = 
0.1845, one-way   ANOVA,   Bonferroni’s  
correction).   This   indicates   that   the   Aβ42 
expressing worms grown on OP50 + 
punicalagin were able to sense and respond 
to the aversive cue at levels similar to 
worms  not  expressing  Aβ42. The avoidance 
indices for worms grown on 
OP50 with 0.27% ethanol to 
control for the punicalagin 
tests are shown in Figure 18. 
 There was a significant 
difference in the avoidance 
index of CL 2355 at 23°C 
(0.19 ± 0.03237) to CL 2355 at 
16°C (0.73 ± 0.01215) (p < 
0.0001, one-way ANOVA, 
Bonferroni’s   correction),  
indicating a deficit in the 
worms’   chemosensation,  
similar to the results gathered 
during baseline testing. The 
Figure 18. Avoidance index of N2, CL2122, and CL2355 at various 
temperatures on NGM plates with punicalagin. 
Avoidance Index of C.elegans Grown on 
OP50 + Punicalagin with 0.1% SDS in M9 
Figure 17. Avoidance index of N2, CL2122, and CL2355 at various temperatures on 
NGM plates with 0.27% ethanol. 
Avoidance Index of C.elegans Grown on 
OP50 + 0.27% Ethanol with 0.1% SDS in M9 
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CL 2122 worms grown at 23°C also exhibited a lower avoidance index (0.20 ± 0.07296), which 
was a result of high levels of response to the control chemical.  
4.2.2 Chemotaxis Assay 
 Similar to the results of baseline testing, N2 strains grown on OP50 at 20°C with 
punicalagin had a chemotaxis index of 0.75 ± 0.04636. Figure 19 shows the chemotaxis indices 
for all worms grown on OP50 with punicalagin. 
 Similar to the results seen from the avoidance assay, punicalagin showed a rescuing effect. 
There was no significant difference between the chemotaxis indices of CL 2355 at 25°C (0.56 ± 
0.02169) and at 16°C (0.58 ± 0.04353) (p > 0.9999, one-way  ANOVA,  Bonferroni’s  correction).  
This indicated that when grown on OP50 with punicalagin, the chemosensory deficit previously 
seen during baseline testing was eliminated. All strains were also grown on OP50 with 0.27% 
ethanol to serve as control. Figure 20 shows the chemotaxis indices for all worms grown on OP50 
with 0.27% ethanol.  
Figure 19. Chemotaxis Index of N2, CL 2122, and CL 2355 at various 
temperatures on NGM plates with punicalagin. 
Chemotaxis Index of C.elegans Grown 
on OP50 + Punicalagin with 10-2 IAA 
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 The results obtained for 
worms grown on OP50 with 
0.27% ethanol were similar to 
those of baseline. There was a 
significant difference in the 
chemotaxis indices of CL 2355 
at 25°C (0.26 ± 0.01526) and CL 
2355 at 16°C (0.55 ± 0.03098) (p 
< 0.0001, one-way ANOVA, 
Bonferroni’s   correction),   which  
indicates  a  deficit  in  the  worms’  
chemosensation. This ethanol 
control result indicated that the 
rescuing effects seen in Figure 
19 were only due to the addition 
of punicalagin, and not due to 
the presence of the ethanol. 
4.2.3 Thrashing Assay 
 This assay was 
performed to evaluate the 
effect of punicalagin on the 
worms  expressing  Aβ42 pan-
muscularly. Figure 21 shows 
the thrash count per minute 
of all worms grown on OP50 
with punicalagin.  
 In contrast to the 
results from the avoidance 
and chemotaxis assays, the 
addition of punicalagin did 
not have an effect on the 
Figure 21. Chemotaxis Index of N2, CL 2122, and CL 2355 at various temperatures 
on NGM plates with 0.27% ethanol. 
Chemotaxis Index of C.elegans Grown 
on OP50 + 0.27% Ethanol with 10-2 IAA 
Figure 20. Thrash count per minute of N2, CL802, and CL4176 at various temperatures 
on NGM with punicalagin plates. 
Thrash Count per Minute of C. elegans 
Grown on OP50 + Punicalagin in M9 
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impaired movement seen  in  worms  expressing  Aβ42 peptide in their muscle cells. There was no 
significant difference in the thrash count per minute of CL 4176 at 25°C (22.50 ± 5.041) to CL 
4176 at 16°C (31.75 ± 12.32) and to CL 802 at 25°C (24.75 ± 4.820) (p = 0.5497 and p > 0.9999, 
one-way  ANOVA,  Bonferroni’s  correction).  This  indicated  that  punicalagin  had  no  rescuing  effect  
in  the  worms  expressing  Aβ42 pan-muscularly. Figure 22 shows the thrash count per minute for all 
worms grown on OP50 with 0.27% ethanol. 
 The results obtained from the 
thrashing assay revealed similar 
thrash counts to those obtained 
in baseline testing. There was no 
significant difference between 
CL 4176 at 25°C (44.5 ± 17.39)  
to      CL 4176 at 16°C (30.00 ± 
7.927) and CL 802 at 25°C 
(23.00 ± 7.439) (p = 0.5764 and 
p > 0.9999, one-way ANOVA, 
Bonferroni’s   correction),   still  
indicating impaired movement 
of  the  worms  expressing  Aβ42.  
 
 
 
 
 
 
 
 
Figure 22. Thrash count per minute of N2, CL802, and CL4176 at various temperatures on 
NGM plates with 0.27% ethanol. 
Thrash Count per Minute of C. elegans 
Grown on OP50 + 0.27% Ethanol in M9 
36 
 
4.3 Tannic Acid 
 To assess the effects of 
tannic acid on the phenotypes 
seen   in   strains   expressing   Aβ42 
peptide, all strains were grown on 
NGM plates seeded with OP50 
and  20  μM  tannic  acid. 
4.3.1 Avoidance Assay 
 The avoidance assay was 
used to test the effects of tannic 
acid   on   the   worms’  
chemosensation. N2 worms 
grown on OP50 with tannic acid 
yielded an avoidance assay of 
0.69 ± 0.02868. Figure 23 shows 
the avoidance indices for all 
worms grown on OP50 with 
tannic acid. 
 Following an upshift in temperature, CL 2355 grown on OP50 with tannic acid showed 
impaired chemosensation as seen with the avoidance index similar to those of baseline testing 
(0.14 ± 0.01947). Furthermore, there was a significant difference in the avoidance indices of CL 
2355 at 23°C to CL 2355 at 16°C (0.71 ± 0.04002) and to CL 2122 at 23°C (0.44 ± 0.03403) (p < 
0.0001 for both, one-way ANOVA,  Bonferroni’s  correction).  This  indicated  that  tannic  acid  has  
no  rescuing  effect  on  the  neuronal  deficits  caused  by  Aβ42 expression. 
4.3.2 Chemotaxis Assay 
 The  chemotaxis  assay  was  also  used  to  evaluate  the  effects  of  tannic  acid  on  the  worms’  
chemosensation abilities. N2 worms grown on OP50 at 20°C with tannic acid had a chemotaxis 
index of 0.70 ± 0.02545. Figure 24 shows the chemotaxis indices for all worms grown on OP50 
with tannic acid. 
Figure 23. Avoidance index of N2, CL2122, and CL2355 at various temperatures 
on NGM plates with tannic acid. 
Avoidance Index of C.elegans Grown on 
OP50 + Tannic Acid with 0.1% SDS in M9 
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 Similar to results 
obtained during baseline 
testing, the chemotaxis index 
of CL 2355 at        25°C   (0.26 
± 0.03493) was significantly 
lower than CL 2355 at 16°C 
(0.73 ± 0.08363) and to CL 
2122 at 25°C (0.71 ± 0.04931) 
(p < 0.0001 for both, one-way 
ANOVA,   Bonferroni’s  
correction). This indicted that 
tannic acid had no effect on the 
deficit seen in the 
chemosensation ability of 
worms  expressing  Aβ42. 
 
4.3.3 Thrashing Assay 
 This assay was performed to evaluate the effect of tannic acid on the muscular abilities of 
the worms. Figure 25 shows the thrash count per minute of all worms grown on OP50 with tannic 
acid. 
Figure 24. Chemotaxis Index of N2, CL 2122, and CL 2355 at various temperatures 
on NGM plates with tannic acid. 
Chemotaxis Index of C.elegans Grown 
on OP50 + Tannic Acid with 10-2 IAA 
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 The addition of tannic acid 
yielded no effect on the impaired 
movement of worms expressing 
Aβ42. This was seen from the not 
significantly different thrash count 
per minute of CL 4176 at 25°C 
(33.75 ± 9.196) to CL 4176 at 16°C 
(17.50 ± 8.067) and CL 802 at 25°C 
(22.75 ± 5.406) (p = 0.6091 and p > 
0.9999, one-way ANOVA, 
Bonferroni’s  correction). 
 
 
 
 
4.4 Treatment Comparisons 
Based on the results, punicalagin demonstrated a neuroprotective effect against the 
behavioral  deficit  seen  in  worms  expressing  Aβ42 pan-neuronally. However, it does not show the 
same  protective  effect  in  worms  expressing  Aβ42 pan-muscularly. In contrast, tannic acid did not 
show   any   rescuing   effect   on  worms   expressing  Aβ42 either pan-neuronally or pan-muscularly. 
Figure 26 depicts the comparison between avoidance indices of CL 2122 and CL 2355 grown at 
all conditions.  
Figure 25. Thrash count per minute of N2, CL802, and CL4176 at various 
temperatures on regular NGM plates with tannic acid. 
Thrash Count per Minute of C. elegans 
Grown on OP50 + Tannic Acid in M9 
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Evidence  of  the  effect  of  Aβ42 expression is seen with the significant difference of the avoidance 
indices of CL 2355 on OP50 with  and  without  an  upshift  in  temperature.  Aβ42 expression reduces 
the avoidance index from 0.76 ± 0.029 to 0.33 ± 0.049 (p < 0.0001, one-way ANOVA, 
Bonferroni’s  correction).  This  indicates  a  defect in the worms’ chemosensation since the worms 
were unable to sense the repellent chemical as aversive. However, when CL 2355 was grown on 
OP50 with punicalagin at 23°C, the behavioral defect was alleviated, evidenced by the avoidance 
index returning to 0.74 ± 0.013, a high level of avoidance. In contrast, CL 2355 grown on OP50 
with tannic acid with the upshift in temperature did not display the same effect. These worms had 
a significantly lower avoidance index (0.14 ± 0.019) compared to CL 2355 grown on OP50 at        
23°C (0.33 ± 0.049) (p = 0.0021, two-way  ANOVA,  Tukey’s  correction).  This  suggests  that  tannic  
acid  may  have  had  a  toxic  effect  on  the  worms’  behavior  or  development,  which  could  affect  their  
ability to sense and respond to the aversive cues. 
Figure 26. Comparison of avoidance indices of CL2122 and CL2355 grown at various temperatures on NGM plates 
with OP50, OP50 + Punicalagin, and OP50 + Tannic Acid. 
Avoidance Index of C.elegans Grown on OP50, OP50 + 
Punicalagin, and OP50 + Tannic Acid with 0.1% SDS in M9 
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 The  second  assay  used  to  test  the  worms’  chemosensory  abilities  was  the  chemotaxis  assay.  
Figure 27 depicts the comparison between chemotaxis indices of CL 2122 and CL 2355 grown at 
all conditions.  
 
The  effect   of  Aβ42 expression is seen with the significant difference of the chemotaxis 
indices of CL 2355 on OP50 with and without an upshift in temperature, which reduces the 
chemotaxis index from 0.61 ± 0.067 to 0.25 ± 0.116 (p = 0.0041, one-way  ANOVA,  Bonferroni’s  
correction). Consistent with the results gathered from the avoidance assay, this indicates a defect 
in the worms chemosensory as the worms were not attracted to the attractant chemical. Similarly, 
punicalagin alleviated the behavioral defect, as seen by a higher chemotaxis index of 0.56 ± 0.022, 
which is significantly different from the chemotaxis index of CL 2355 grown on OP50 alone with 
the upshift in temperature (p = 0.0012, two-way   ANOVA,   Tukey’s   correction).   Furthermore,        
CL 2355 grown on OP50 with tannic acid with the upshift in temperature did not display any effect 
(0.26 ± 0.035), seen from its low chemotaxis index that is not significantly different from that of 
Figure 27. Comparison of chemotaxis indices of CL2122 and CL2355 grown at various temperatures on NGM plates 
with OP50, OP50 + Punicalagin, and OP50 + Tannic Acid. 
Chemotaxis Index of C.elegans Grown on OP50, OP50 + Punicalagin, 
and OP50 + Tannic Acid with 10-2 IAA 
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CL 2355 on OP50 with the upshift in temperature (0.25 ± 0.116)  (p = 0.9842, two-way ANOVA, 
Tukey’s  correction). 
 The  last  assay  used  in  this  project  was  the  thrashing  assay,  which  tested  the  effect  of  Aβ42 
on  the  worms’  muscular  abilities.  Figure  28  depicts  the  thrash  count  per  minute  of  CL  4176  under  
all tested conditions.  
 The  effect  of  Aβ42 expression on muscle cells can be seen from the significantly different 
thrash count per minute of CL 4176 grown on OP50 with and without an upshift in temperature. 
The thrash count per minute went from 53.25 ± 11.456 thrashes per minute to 20.50 ± 7.005 
thrashes per minute (p = 0.0349, one-way  ANOVA,  Bonferroni’s   correction).  This   behavioral  
defect   caused   by   the  Aβ42 expression was characterized as impaired movement. Furthermore, 
neither extract tested had any effect on the behavioral defect, as seen from the similar thrash count 
per minute from worms grown on OP50 to OP50 with punicalagin or tannic acid with the upshift 
in temperature (p > 0.9999 and p = 0.4793, two-way  ANOVA,  Bonferroni’s  correction).  Therefore,  
in  contrast  to  the  alleviation  of  behavioral  defects  seen  in  worms  expressing  Aβ42 pan-neuronally, 
none of the extracts tested displayed the same effect on worms  expressing  Aβ42 pan-muscularly. 
Figure 28. Comparison of thrash count per minute of CL 802 and CL4176 grown at various temperatures on NGM 
plates with OP50, OP50 + Punicalagin, and OP50 + Tannic Acid. 
Thrash Count per Minute of C.elegans Grown on OP50, OP50 + 
Punicalagin, and OP50 + Tannic Acid in M9 
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There was also a significant difference in the thrash count per minute between CL 4176 grown on 
OP50  and  OP50  with  tannic  acid  without  an  upshift  in  temperature  nor  expression  of  Aβ42 (p = 
0.0159, two-way ANOVA, Bonferroni’s  correction).  This  suggests that tannic acid might have a 
toxic  effect  on  the  worms’  movement  response  even  without  Aβ42 expression. 
 It should be noted that the method used to analyze the results of the thrashing assay in this 
study has not been standardized. The method of analysis used was developed by the researchers of 
this project and therefore further improvements can be made to produce a more robust 
representation of the data.   
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5 Conclusions and Future Work 
From this study we have verified three behavioral assays that can be used to evaluate the 
behavioral effects of Aβ42 expression in C. elegans. Two of these assays test the chemosensation 
of worms expressing Aβ42 in neuronal cells, while the third tests the movement of worms 
expressing the protein in muscle cells. Versions of these tests have been used before for behavioral 
testing,  but  not  in  the  context  of  an  Alzheimer’s  disease  model.  Each  assay  showed  a  reduction in 
neuroperformance when the animals were heat-shocked to initiate Aβ42 expression. This indicates 
that these assays are appropriate tools to measure these behavioral phenotypes. These phenotypes 
are   analogous   to   human   Alzheimer’s   disease   symptoms   of   impaired olfactory ability and 
dysfunction of movement.  
From the results, we are able to conclude that the polyphenol punicalagin mitigates the 
behavioral defects in C. elegans caused by Aβ42 protein expression in neuronal cells. This 
therapeutic effect was not seen in worms expressing Aβ42 protein in muscle cells. There are various 
possible explanations for this dissimilar effect. One explanation is that the worms expressing Aβ42 
in muscle cells exhibited a roller phenotype caused by expression of the gene rol-6. This gene 
itself impairs movement of the worms with or without Aβ42 expression (Kramer, French and Park), 
so it would likely be more difficult for any potential rescue effect to be observed. The assay used 
to analyze the impaired movement of these worms could also be improved upon. Data analysis 
was done using thrash count, but WormLab software has a variety of options for analyzing worm 
movement, including speed, direction of movement, worm position, and track length. It is possible 
that one of these other analysis methods would more accurately display differences between the 
test strains and treatment groups. A third possible explanation is that the mechanism of action is 
different in neuronal cells than muscle cells. Studies have shown that Aβ42 is more likely to 
accumulate in plaques in the brain, while Aβ40, which is more soluble, tends to accumulate between 
muscle cells (Serrano-Pozo, Frosch and Masliah). Punicalagin may have been able to interfere 
with Aβ42 expression of the neuronal cells but not the muscle cells and so only rescued the behavior 
in strains expressing Aβ42 pan-neuronally. 
Tannic acid, unlike punicalagin, was unable to mitigate any of the behavioral effects. This 
was surprising, as previous  studies  have  implicated  tannic  acid  as  a  good  candidate  for  Alzheimer’s  
disease therapeutics (Ono, Hasegawa and Naiki). Other studies have shown that tannic acid can be 
toxic at high levels (Khan, Ahmad and Hadi), providing some insight into these unexpected results. 
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In the avoidance assay, the worms responded to the control chemical at relatively high levels, 
similar to the worms grown on OP50 and ethanol. Qualitative observation of these worms also 
indicated that not all worms placed on a plate survived to adulthood, and that the worms grew 
more slowly. If there was a developmental defect caused by the tannic acid this may have been a 
confounding   variable   that   further   worsened   the   worms’   chemosensory   abilities.   Further  
understanding of this effect can be achieved by testing various concentrations of tannic acid to 
determine if lower concentrations continue to cause this effect. We tested concentration of tannic 
acid was chosen based on previous studies performed with neuronal cells (Ono, Hasegawa and 
Naiki). We chose to increase the concentration used on these cells, because we believed that C. 
elegans would be able to withstand a higher dose, as it is a fully developed organism. It is possible 
that the concentration chosen was too high, so a return to the concentration of 0.1µM used by Ono 
in 2004 could give more insight to this. Researchers could also use even lower concentrations, in 
case there were toxic effects on the cells used by Ono that could not be observed in vitro (Ono, 
Hasegawa and Naiki). 
Worms were placed on OP50 with or without extracts as eggs and allowed to hatch and 
mature all while feeding on the extract being tested. This leads us to believe that the punicalagin 
prevented the symptoms from ever manifesting in the worms, rather than cured symptoms that 
were already  present.  Since  most  cases  of  Alzheimer’s  disease  are  diagnosed  after  the  disease  has  
taken hold of the patient, it would be useful to test punicalagin as a retroactive cure as well, where 
the Aβ42 expression is induced prior to treatment with punicalagin. In addition to investigating the 
ability of punicalagin to alleviate behavioral symptoms retroactively, this could also give some 
insight into the mechanism behind the therapeutic effect of the extract. If punicalagin were simply 
blocking Aβ42 gene expression then retroactive treatment might not be successful. If punicalagin 
is removing the Aβ42 post-accumulation or reducing oxidative stress, the retroactive treatment 
might still have a similar effect. Further analysis to understand why punicalagin had this 
neuroprotective effect would be necessary before any clinical applications of the compound could 
be investigated. This could include a biochemical analysis of how much punicalagin is ingested 
by the worms and how it is distributed and digested.   
Researchers could take this project a step further and investigate the role of gender bias in 
the symptoms shown from the Aβ42 peptides. In humans, women are approximately twice as likely 
to develop Alzheimer’s  disease  as  men (Alzheimer's Association). Since C. elegans is a sexually 
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dimorphic organism, researchers could investigate whether there are sex-specific behavioral 
defects caused by the expression of Aβ42 peptides. While not a male-female system, the differences 
between male and hermaphrodite C. elegans could provide some insight into the different 
mechanisms driving Aβ42 expression and accumulation in different genders. 
In order to fully validate the use of CL 2355 and CL 4176  as  models  of  human  Alzheimer’s  
disease, researchers should investigate whether or not the Aβ42 that is expressed following growth 
at a temperature upshift is actually forming the amyloid plaques that are a hallmark of the disease. 
Lublin and Link explain that it is unlikely that C. elegans models can completely mimic human 
Alzheimer’s  disease  pathology  (Lublin and Link), however the accumulation into plaques is an 
important aspect of the disease. This also underscores the need for further testing of punicalagin 
and any other extracts implicated in invertebrate models in mammalian models before looking into 
the effects on human patients.  
This study provides a preliminary analysis of the effects of punicalagin and tannic acid on 
C. elegans expressing Aβ42 in either neuronal or muscular cells. This is a promising platform for 
furthering our understanding of this devastating disease. C. elegans provides a system that can 
show altered behavioral phenotypes caused by Aβ42 expression and can be studied at the molecular 
level to understand the mechanisms and pathways driving these changes. It is also valuable that 
these worms show deficits in multiple aspects of behavior, allowing for validation of results 
between assays and for the study of various effects of the disease. This study successfully 
characterized the behavioral effects of Aβ42 expression in three separate assays and found that 
punicalagin has the potential to mitigate the effects of this expression. Hopefully future research 
will  continue  to  make  breakthroughs  in  the  understanding  of  Alzheimer’s  disease  and  the  search  
for a cure. 
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6 Appendix 
6.1 Appendix A: Isoamyl Alcohol Dilution 
In order to create 1 μM solution of isoamyl alcohol (3-methyl-1-butanol), the desired mass 
to  be  diluted  was  first  calculated  from  its  molecular  weight.  Isoamyl  alcohol  (IAA)’s  molar  mass  
of 88.15 g/mol was divided by 4 x 104 moles. The mass to be diluted to achieve a concentration of 
1mM IAA with a volume of 25 mL was 0.00220375 g or 22.0375 x 10-4 g. This value was 
confirmed using Sigma-Aldrich’s  Mass  Molarity  Calculator. The mass of 22.0375 x 10-4 g was 
then divided by its density, 0.809 g/mL (Sigma-Aldrich), to obtain the desired volume needed. 
Therefore,   2.724  μL  of   1  M   IAA  was  diluted  with  25  mL  of  ultrapure  water   to  obtain   a   final  
concentration of 1mM IAA. The solution was made in a 50 mL conical tube. Another dilution was 
then  performed  to  obtain  a  final  concentration  of  1μM  IAA.  9.99  μL  of  the  1  mM  stock  solution  
of IAA was diluted in 10 mL of ultrapure water, obtaining  a  final  concentration  of  1  μM  IAA.  
From  the  1  μM  solution,  aliquots  of  1  mL  were  distributed  in  amber  vials. The conical tubes and 
the amber vials were wrapped with aluminum foil to protect the stock solutions from the light and 
were stored at 4°C. The initial stock solution bottle of IAA was kept in the flammables container. 
All dilution work was performed in a chemical hood with proper ventilation to avoid inhalation of 
IAA. 
These aliquots were used for the attraction assay during the experimentation process of the 
project. However, when they were used for chemotaxis assay, these aliquots did not elicit the most 
robust index. Therefore, new concentrations of IAA were made for the chemotaxis assay. The 
working stock had a final concentration of 10-2. This was done by adding 100 µl of the concentrated 
stock IAA (98%) into 900 µl of ultrapure water for the first dilution, creating a concentration of 
10-1. Then, 100 µl of the first dilution of IAA (10-1) were added to another 900 µl of purified water 
to achieve the second dilution of 10-2 concentration. These concentrations were decided to be the 
best as it produces the most robust chemotaxis response. The working stock of IAA was placed in 
an amber vial, which was stored in the 4°C fridge. All work was performed in the hood to avoid 
inhalation of IAA. 
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6.2 Appendix B: Diacetyl Dilution 
In order to create 1 μM solution of diacetyl (butane-2,3-dione), the desired mass to be diluted was 
first  calculated  from  its  molecular  weight.  Diacetyl’s  molar  mass  of  86.09 g/mol was divided by 4 
x 104 moles. The mass to be diluted to achieve a concentration of 1mM diacetyl with a volume of 
25 mL was 0.00215225 g or 21.5225 x 10-4 g. This value was confirmed using Sigma-Aldrich’s  
Mass Molarity Calculator. The mass of 21.5225 x 10-4 g was then divided by its density, 0.981 
g/mL (Sigma-Aldrich), to obtain  the  desired  volume  needed.  Therefore,  2.190  μL  of  1  M  diacetyl 
was diluted with 25 mL of ultrapure water to obtain a final concentration of 1mM diacetyl. The 
solution was made in a 50 mL conical tube. Another dilution was then performed to obtain a final 
concentration  of  1μM  diacetyl.  9.99  μL  of  the  1  mM  stock  solution  of  diacetyl was diluted in 10 
mL of ultrapure water,  obtaining  a  final  concentration  of  1  μM  diacetyl.  From  the  1  μM  solution,  
aliquots of 1 mL were distributed in amber vials. The conical tubes and the amber vials were 
wrapped with aluminum foil to protect the stock solutions from the light and were stored at 4°C. 
The initial stock solution bottle of diacetyl was kept in the flammables container. All dilution work 
was performed in a chemical hood with proper ventilation to avoid inhalation of diacetyl. 
6.3 Appendix C: Attraction Assay 
The assay was developed by Srinivasan et al in 2008 and uses a template as seen in Figure 
29. 24 hours prior to the assay, NGM plates were seeded with LB media containing OP50. Aseptic 
technique was used to seed plates to avoid contamination. Three to four drops of media were added 
to the center of each plate using sterile Pasteur pipettes. A bent glass pipette was flame sterilized 
and used to spread the media. This was accomplished by holding the pipette in place and spinning 
the plate continuously until the media was evenly spread over the agar. Plates were stored at room 
temperature for 20 minutes, and then inverted and stored overnight in a 20°C incubator. Two 
circles with a diameter of 5 mm are drawn on the template to mark the placement of the vehicle 
control and attractant chemicals. The X spots located near the circles are where the worms were 
initially placed in the beginning of each trial. 5 worms are placed on each X spots. 
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0.6 μl of the attractant chemical, 
either isoamyl alcohol or diacetyl, was 
added to one circle of the template on the 
seeded lawn plate. Isoamyl alcohol is a 
colorless alcohol that attracts wild-type 
worms and diacetyl is an organic compound 
with a buttery odor that illicit the same 
attraction in 
wild-type 
worms. 0.6 μl of ultrapure water was added to the other circle on the 
plate to act as the vehicle control. Once all of the chemicals had been 
added, worms were added to the test plate. The lid of the plate was 
removed and a modified plastic bowl was placed around the plate to 
avoid in any effects from any cross-breeze in the lab during recording 
as seen in Figure 30. Each plate was recorded for 20 minutes with a 
total of 5 plates tested for one session. The video was then analyzed by 
scoring the amount of time of each visit to the control versus attractant 
drops.  
 
6.4 Appendix D: Supplemental Data of CL 2006 on All Conditions 
 In  addition  to  CL  4176,  the  strain  CL  2006  was  also  used  as  a  constitutive  Aβ  strain  that  
expresses  Aβ  pan-muscularly. This strain was tested using the thrashing assay to evaluate the 
effect  of  Aβ  on  the  worms’  movement  and  also  to  assess  the  effects  of  punicalagin  and  tannic  
acid  on  the  worms’  muscle  cells. 
Figure 29. Attraction assay template on NGM testing plate (Based 
on Srinivasan, 2008). 
Figure 30. Microscope setup to 
record the attraction assay. 
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 As seen in Figure 31, which outlines the thrash count per minute of CL 2006 at all 
conditions  on  various  temperatures,  the  impaired  movement  caused  by  the  Aβ42 can be seen from 
CL 2006 at 25°C on OP50, which shows a thrash count of 30.5 ± 5.679 thrashes per minute. 
Furthermore, there are no significant difference between the thrash count per minute of CL 2006 
at 16°C grown on OP50 with those grown on OP50 with punicalagin, OP50 with tannic acid, or 
OP50 with 0.27% ethanol (p = 0.0679, p > 0.9999, and p > 0.9999, two-way ANOVA, 
Bonferroni’s  correction). Therefore, it is evident that none of the treatments had an effect on the 
impaired  movement  caused  by  the  Aβ42 peptide. 
   
Figure 31. Thrash count per minute of CL 2006 grown on with either OP50, OP50 + Punicalagin, OP50 + Tannic 
Acid, or OP50 + 0.27% ethanol at various temperatures. 
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